OptimUM-02
86 evidence topics · 20 sources
Objective
Study purpose in the ClinicalTrials.gov record
Phase 2a, phase 2b, and phase 3 objectives in the EU trial record
Secondary objectives in the EU trial record
Aim of the primary analysis in the ASCO 2026 abstract
Aim of the subgroup analysis in the ESMO 2026 poster
Location and study date
Study status, dates, and number of sites in the ClinicalTrials.gov record
| Study characteristic | Quoted record |
|---|---|
| Overall status | “Active, not recruiting” |
| Study start (actual) | “2023-10-31” |
| Primary completion (estimated) | “2027-01-15” |
| Study completion (estimated) | “2028-01-15” |
| Sites | “This study has 68 locations” |
| Last update posted | “Last Update Posted 2026-02-17” |
Countries with listed sites in the ClinicalTrials.gov record
| Country | Example of a listed site location |
|---|---|
| United States | “Philadelphia, Pennsylvania, United States, 19107” |
| Australia | “Melbourne, Victoria, Australia, 3000” |
| Belgium | “Brussels, Belgium, 1200” |
| Canada | “Toronto, Ontario, Canada, M5G 2M9” |
| France | “Paris, France, 75005” |
| Germany | “Heidelberg, Baden-Wurttemberg, Germany, 69120” |
| Israel | “Jerusalem, Israel, 91120” |
| Italy | “Milan, Italy, 20133” |
| Netherlands | “Leiden, Netherlands, 2333 ZA” |
| Poland | “Warsaw, Poland, 02-781” |
| Spain | “Madrid, Spain, 28046” |
| Switzerland | “Zurich, Switzerland, 8058” |
| United Kingdom | “Glasgow, United Kingdom, G12 0YN” |
European Union dates in the EU trial record
| Field | Quoted record |
|---|---|
| Start date in the European Union | “2024-10-09” |
| Estimated recruitment start date | “2024-07-01” |
| Estimated global end date | “2027-12-31” |
Enrollment progress in December 2024
Enrollment progress and international sites as of February 2025
Data cutoff of the primary analysis presented at ASCO 2026
Subgroup analysis presented at ESMO 2026
Study design
Multi-stage randomized open-label design in the ClinicalTrials.gov record
Allocation, assignment model, and masking in the ClinicalTrials.gov record
| Design characteristic | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
Randomization ratios and stratification factors in the ASCO 2026 presentation
Randomization of first-line HLA-A2-negative participants in the ASCO 2026 abstract
Random assignment in the phase 2b and phase 3 portions as reported from the ASCO 2026 presentation
Integrated study-in-study design after the FDA Type C meeting, April 2023
Completion of phase 2a dose optimization on an independent data monitoring committee recommendation, December 2024
Crossover from the control arm
No evidence found.
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
| Inclusion criterion | Quoted record |
|---|---|
| Diagnosis | “Histological or cytological confirmed Metastatic Uveal Melanoma” |
| HLA type required | “HLA-A*02:01 negative” |
| Prior therapy | “No prior systemic therapy in the metastatic or advanced setting regional or liver-directed therapy. Ablations or surgical resection of oligometastatic disease, and neoadjuvant or adjuvant therapy is allowed” |
| Measurable disease | “Measurable disease per RECIST 1.1” |
| Ability to take study therapy | “Able to be safely administered and absorb study therapy” |
| Performance status | “ECOG performance status 0 or 1” |
| Life expectancy | “Life expectancy of ≥3 months” |
| Organ function | “Adequate organ function” |
| Ages eligible | “18 Years and older (Adult, Older Adult )” |
Exclusion criteria in the ClinicalTrials.gov record
Prior treatment requirements in the EU trial record
Tissue, measurable disease, and first-line status in the EU trial record
Laboratory thresholds for adequate organ function in the EU trial record
Syncope, cardiac, and concomitant medication exclusions in the EU trial record
Contraindication to comparator options and restricted use of dacarbazine in the EU trial record
Treatment
Darovasertib and crizotinib doses, run-in, and comparator regimens in the ASCO 2026 presentation
| Arm or regimen | Dose shown in the study design figure |
|---|---|
| Phase 2a and phase 2b/3 selected-dose arm, darovasertib | “Darovasertib (300 mg BID)” |
| Phase 2a and phase 2b/3 combination arms, crizotinib | “Crizotinib (200 mg BID)” |
| Phase 2a lower-dose arm, darovasertib | “Darovasertib (200 mg BID)” |
Route and schedule of each intervention in the ClinicalTrials.gov record
| Intervention | Quoted route and schedule |
|---|---|
| IDE196 (darovasertib) and crizotinib | “Dosed orally, twice daily” |
| Pembrolizumab | “IV administration every 3 weeks” |
| Ipilimumab | “IV administration every 3 weeks for 4 Cycles” |
| Nivolumab | “IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance” |
| Dacarbazine | “IV administration every 3 Weeks” |
Comparator stratum in the investigator's choice arm (ASCO 2026 presentation)
| Investigator's choice treatment at baseline (stratification), n (%) | Investigator's choice arm (N=103) |
|---|---|
| Ipilimumab + nivolumab | “79 ( 76.7)” |
| Pembrolizumab or dacarbazine | “24 ( 23.3)” |
Comparator selection in the investigator's choice arm, ESMO 2026 poster
Comparator received in the control arm as reported from the ASCO 2026 presentation
Comparator composition in the topline release, which differs from the ASCO and ESMO counts
Study outcomes
Rationale for using progression-free survival by blinded independent central review as the primary endpoint
Primary endpoints of each stage in the ClinicalTrials.gov record
Definitions of progression-free survival and overall survival in the EU trial record
Primary and other endpoints in the ASCO 2026 abstract
Median progression-free survival as the accelerated approval endpoint after the FDA Type C meeting, April 2023
Overall survival as the primary endpoint of the phase 3 confirmatory portion in the annual report for 2024
Accelerated approval on a surrogate endpoint as described in the annual report for 2025
Regulatory role of each primary endpoint in the full enrollment release, December 2025
Regulatory role of each primary endpoint in the topline and ASCO 2026 releases
FDA guidance on progression-free survival as a regulatory endpoint
FDA guidance on blinded central review of tumor-based endpoints
FDA guidance on overall survival as an endpoint
FDA draft guidance on a single randomized trial supporting accelerated approval and verifying benefit
Historical progression-free and overall survival in metastatic uveal melanoma cited in the ESMO 2026 poster
Disease control definition and imaging interval as reported from the ASCO 2026 presentation
Secondary efficacy and safety endpoints in the ClinicalTrials.gov record
Definitions of response endpoints in the EU trial record
Patient-reported outcome endpoints in the ClinicalTrials.gov record and the EU trial record
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of 420 participants in the current ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Enrollment (estimated) | “420” |
Planned enrollment of 420 participants from record version 39, November 2024
| Field | Quoted record |
|---|---|
| Record version viewed | “Viewing V39 (2024-11-05)” |
| Enrollment | “420 [Estimated]” |
Planned enrollment of 380 participants in record version 1, August 2023, superseded in November 2024
| Field | Quoted record |
|---|---|
| Record version viewed | “Viewing V1 (2023-08-03)” |
| Enrollment | “380 [Estimated]” |
Planned phase 2 and phase 3 sample sizes after the FDA Type C meeting, April 2023, superseded in December 2025
Completed enrollment of 435 participants in the full enrollment release, December 2025
Completed enrollment of 437 participants in the annual report for 2025
Statistical design of the phase 2b primary analysis in the ASCO 2026 presentation
Participants analyzed in the ASCO 2026 release
Testing hierarchy and alpha allocation for secondary endpoints and overall survival
No evidence found.
Description of analysis sets
Intent-to-treat efficacy population of the phase 2b portion in the ASCO 2026 presentation
Safety population of 338 and efficacy population of 313 in the ASCO 2026 abstract
Stratified and unstratified subgroup models in the ESMO 2026 poster
Results
Participant disposition
Participants without a post-baseline response assessment, by arm (ASCO 2026 presentation)
| Best overall response category | Darovasertib plus crizotinib (N=210), n (%) | Investigator's choice (N=103), n (%) |
|---|---|---|
| Not reported (no post-baseline assessment), by BICR and by investigator | “12 (5.7)” | “24 (23.3)” |
Median follow-up and median duration of treatment in the ASCO 2026 presentation
Discontinuation of study treatment for adverse events, ASCO 2026 abstract
Baseline characteristics
Demographics, performance status, and LDH stratum (ASCO 2026 presentation)
| Characteristic | Darovasertib plus crizotinib (N=210) | Investigator's choice (N=103) |
|---|---|---|
| Age, mean (range), years | “61.1 (22 - 85)” | “61.5 (29 - 85)” |
| Female, n (%) | “101 (48.1)” | “52 (50.5)” |
| Race, White, n (%) | “177 (84.3)” | “83 (80.6)” |
| Race, non-White, n (%) | “4 (1.9)” | “4 (3.9)” |
| Race, not reported, n (%) | “29 ( 13.8)” | “16 ( 15.5)” |
| ECOG 0, n (%) | “162 (77.1)” | “87 (84.5)” |
| ECOG 1, n (%) | “48 (22.9)” | “16 (15.5)” |
| Stratification LDH at baseline (IRT), ≤ ULN, n (%) | “120 (57.1)” | “62 (60.2)” |
| Stratification LDH at baseline (IRT), > ULN to < 2x ULN, n (%) | “65 (31.0)” | “29 (28.2)” |
| Stratification LDH at baseline (IRT), ≥ 2x ULN, n (%) | “25 (11.9)” | “12 (11.7)” |
Baseline tumor characteristics and metastatic sites (ASCO 2026 presentation)
| Characteristic | Darovasertib plus crizotinib (N=210) | Investigator's choice (N=103) |
|---|---|---|
| Time since first metastatic diagnosis, median (range), years | “0.18 (0.0 – 8.1)” | “0.19 (0.0 – 4.6)” |
| Size of largest metastatic lesion ≤ 3 cm, n (%) | “119 ( 56.7)” | “67 ( 65.0)” |
| Size of largest metastatic lesion 3.1 to 8.0 cm, n (%) | “73 ( 34.8)” | “31 ( 30.1)” |
| Size of largest metastatic lesion ≥ 8.1 cm, n (%) | “18 ( 8.6)” | “5 ( 4.9)” |
| Hepatic disease only, n (%) | “127 ( 60.5)” | “65 ( 63.1)” |
| Extrahepatic disease only, n (%) | “11 ( 5.2)” | “7 ( 6.8)” |
| Hepatic and extrahepatic disease, n (%) | “72 ( 34.3)” | “31 ( 30.1)” |
Comparator stratum and prior oligometastatic surgery (ESMO 2026 poster)
| Characteristic | Darovasertib 300 mg plus crizotinib 200 mg (N=210) | Investigator's choice (N=103) |
|---|---|---|
| Control at baseline, ipilimumab + nivolumab, n (%) | “158 (75.2)” | “79 ( 76.7)” |
| Control at baseline, pembrolizumab or dacarbazine, n (%) | “52 (24.8)” | “24 ( 23.3)” |
| Prior oligometastatic-directed surgery, n (%) | “5 (2.4)” | “6 (5.8)” |
Balance of baseline characteristics as reported from the ASCO 2026 presentation
Efficacy results
Progression-free survival, 313 participants of the phase 2b/3 portion, data cutoff January 23, 2026
| Outcome | By blinded independent central review | By investigator assessment |
|---|---|---|
| Median PFS, darovasertib plus crizotinib, months (95% CI) | “Darova + Criz: 6.9 (5.6, 8.3)” | “Darova + Criz: 6.7 (5.6, 8.2)” |
| Median PFS, control, months (95% CI) | “Control: 3.1 (1.8, 4.2)” | “Control: 2.7 (1.7, 4.1)” |
| Hazard ratio (95% CI) | “HR = 0.42 (0.30, 0.59)” | “HR = 0.36 (0.26, 0.50)” |
Objective response, best overall response, duration of response, and disease control, 210 and 103 participants by arm
| Outcome | BICR, darovasertib plus crizotinib (N=210) | BICR, investigator's choice (N=103) | Investigator, darovasertib plus crizotinib (N=210) | Investigator, investigator's choice (N=103) |
|---|---|---|---|---|
| Complete or partial response, n (%) | “78 (37.1)” | “6 (5.8)” | “83 (39.5)” | “2 (1.9)” |
| Objective response rate, 95% CI | “30.6, 44.1” | “2.2, 12.3” | “32.9, 46.5” | “0.2, 6.8” |
| Objective response, odds ratio (95% CI) | “10.8 (4.4, 26.4)” | Reference | “34.6 (8.1, 146.9)” | Reference |
| Median duration of response, months (95% CI) | “6.8 (5.5, 11.3)” | “NE” | “6.8 (4.8, 9.7)” | “NE” |
| Complete response, partial response, or stable disease for at least 12 weeks, n (%) | “154 (73.3)” | “32 (31.1)” | “156 (74.3)” | “28 (27.2)” |
| Disease control rate, 95% CI | “66.8, 79.2” | “22.3, 40.9” | “67.8, 80.1” | “18.9, 36.8” |
| Disease control, odds ratio (95% CI) | “7.7 (4.3, 13.5)” | Reference | “9.5 (5.3, 17.0)” | Reference |
| Best overall response, n (%) | BICR, darovasertib plus crizotinib (N=210) | BICR, investigator's choice (N=103) | Investigator, darovasertib plus crizotinib (N=210) | Investigator, investigator's choice (N=103) |
|---|---|---|---|---|
| Complete response | “5 (2.4)” | “0” | “0” | “0” |
| Partial response | “73 (34.8)” | “6 (5.8)” | “83 (39.5)” | “2 (1.9)” |
| Stable disease | “107 (51.0)” | “43 (41.7)” | “99 (47.1)” | “39 (37.9)” |
| Progressive disease | “13 (6.2)” | “29 (28.2)” | “15 (7.1)” | “34 (33.0)” |
| Non-evaluable by RECIST | “0” | “1 (1.0)” | “1 (0.5)” | “4 (3.9)” |
Response, disease control, and duration of response, ASCO 2026 abstract
Tumor shrinkage on waterfall plots and subgroup consistency as reported from the ASCO 2026 presentation
Objective response and median progression-free survival by BICR in subgroups, efficacy population of 313 participants (ESMO 2026 poster, stratified analysis)
| Subgroup (n, darovasertib plus crizotinib and control) | ORR by BICR, darovasertib plus crizotinib (%) | ORR by BICR, control (%) | Median PFS by BICR, darovasertib plus crizotinib (months) | Median PFS by BICR, control (months) |
|---|---|---|---|---|
| LDH normal (n=120, 62) | “46.7” | “8.1” | “8.4” | “4.2” |
| LDH above ULN and below 2x ULN (n=65, 29) | “27.7” | “3.4” | “5.7” | “1.8” |
| LDH 2x ULN or higher (n=25, 12) | “16.0” | “0” | “3.1” | “1.7” |
| Hepatic metastases (n=127, 65) | “45.7” | “3.1” | “8.3” | “2.9” |
| Extrahepatic metastases only (n=11, 7) | “27.3” | “0” | “6.7” | “8.3” |
| Hepatic and extrahepatic metastases (n=72, 31) | “23.6” | “12.9” | “4.9” | “2.8” |
| ECOG PS 0 (n=162, 87) | “38.3” | “5.8” | “6.8” | “3.1” |
| ECOG PS 1 (n=48, 16) | “33.3” | “6.3” | “6.9” | “3.1” |
| Largest lesion below 3 cm (n=119, 67) | “42.9” | “6.0” | “8.3” | “4.0” |
| Largest lesion 3 to 8 cm (n=73, 31) | “34.3” | “6.5” | “5.6” | “1.6” |
| Largest lesion 8 cm or larger (n=18, 5) | “11.1” | “0” | “4.2” | “1.7” |
| Control stratum ipilimumab plus nivolumab (n=158, 79) | “37.3” | “5.1” | “6.9” | “3.1” |
| Control stratum pembrolizumab or dacarbazine (n=52, 24) | “36.5” | “8.3” | “5.8” | “2.8” |
Subgroup findings in the ASCO 2026 and ESMO 2026 releases
Overall survival status at the primary analysis
Secondary endpoint wording in the quarterly report for the first quarter of 2026, which differs from the releases and the presentation
Health-related quality of life and patient-reported outcomes
Quality-of-life data not presented at the ASCO 2026 primary analysis
Safety results
Treatment-related adverse events, phase 2a and 2b safety population of 239 and 100 participants (ASCO 2026 presentation)
“Darovasertib 300mg + crizotinib 200 mg (N=239)” (opens the source at this quote in a new tab)
“Investigator’s Choice (control, N=100)” (opens the source at this quote in a new tab)
| Outcome | Darovasertib plus crizotinib (N=239) | Investigator's choice (N=100) |
|---|---|---|
| Any TRAE, n (%) | “235 (98.3)” | “89 (89.0)” |
| Grade 3 or 4 TRAE, n (%) | “97 (40.6)” | “37 (37.0)” |
| Grade 5 TRAE, n (%) | “1 (0.4)” | “1 (1.0)” |
| Treatment-related serious adverse event, n (%) | “22 (9.2)” | “25 (25.0)” |
| TRAE leading to withdrawal, row not naming a drug, n (%) | “2 (0.8)” | “5 (5.0)” |
| TRAE leading to darovasertib withdrawal, n (%) | “6 (2.5)” | Not applicable |
| TRAE leading to crizotinib withdrawal, n (%) | “24 (10.0)” | Not applicable |
| TRAE leading to investigator's choice withdrawal, n (%) | Not applicable | “19 (19.0)” |
| TRAE leading to darovasertib dose reduction, n (%) | “56 (23.4)” | Not applicable |
| TRAE leading to crizotinib dose reduction, n (%) | “63 (26.4)” | Not applicable |
| Most common TRAE of any grade (20% or more), darovasertib plus crizotinib arm | Darovasertib plus crizotinib (N=239), n (%) |
|---|---|
| Any TRAE | “235 ( 98.3)” |
| Diarrhea | “203 ( 84.9)” |
| Nausea | “179 ( 74.9)” |
| Peripheral edema | “160 ( 66.9)” |
| Vomiting | “119 ( 49.8)” |
| Dermatitis acneiform | “100 ( 41.8)” |
| Fatigue | “94 ( 39.3)” |
| Hypotension | “79 ( 33.1)” |
| Hypoalbuminemia, dysgeusia, and dizziness, each | “61 ( 25.5)” |
| Decreased appetite | “57 ( 23.8)” |
| Most common TRAE of any grade (20% or more), investigator's choice arm | Investigator's choice (N=100), n (%) |
|---|---|
| Any TRAE | “88 ( 88.0)” |
| Diarrhea | “29 ( 29.0)” |
| Alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, and nausea, each | “25 ( 25.0)” |
| Pruritus | “24 ( 24.0)” |
| Grade 3 or 4 TRAE (2% or more), darovasertib plus crizotinib arm | Darovasertib plus crizotinib (N=239), n (%) |
|---|---|
| Any grade 3 or 4 adverse event | “97 ( 40.6)” |
| Diarrhea | “24 ( 10.0)” |
| Syncope | “17 ( 7.1)” |
| Hypotension | “9 ( 3.8)” |
| Nausea and peripheral edema, each | “7 ( 2.9)” |
| Anemia | “6 ( 2.5)” |
| Grade 3 or 4 TRAE (2% or more), investigator's choice arm | Investigator's choice (N=100), n (%) |
|---|---|
| Any grade 3 or 4 adverse event | “37 ( 37.0)” |
| Alanine aminotransferase increased and aspartate aminotransferase increased, each | “7 ( 7.0)” |
| Diarrhea | “6 ( 6.0)” |
| Hepatitis | “5 ( 5.0)” |
| Colitis | “4 ( 4.0)” |
| Lipase increased, autoimmune hepatitis, and amylase increased, each | “3 ( 3.0)” |
| Tubulointerstitial nephritis, hypophysitis, and hyperthyroidism, each | “2 ( 2.0)” |
Treatment-emergent adverse events of any cause, ASCO 2026 abstract
Treatment-related serious adverse events of 25.3% in the control arm, ASCO 2026 abstract
Treatment-related serious adverse events of 25.0% in the control arm and grade 3 or 4 events, ASCO 2026 release
Grade 3 or higher adverse events in the topline release
Management of hypotension and syncope as reported from the ASCO 2026 presentation
Study limitations
Summary
OptimUM-02 is open label, with no masking. The primary analysis was reported at a median follow-up of 7.4 months; OS, the phase 3 primary endpoint, was not mature, and no OS estimate has been reported. The efficacy population of 313 participants is the intent-to-treat population of the phase 2b portion, which the topline release describes as enrolled in the phase 2b/3 portion; the safety analyses use different denominators, 338 participants in the ASCO 2026 abstract and 239 and 100 participants from phases 2a and 2b in the presentation. Reported enrollment is 435 participants in the full enrollment release and 437 in the annual report for 2025.
The comparator was investigator's choice: 79 participants (76.7%) received ipilimumab plus nivolumab, 24 (23.3%) pembrolizumab, and none dacarbazine (the topline release gives 78 and 25), and the EU trial record restricts dacarbazine to settings where immunotherapy is deemed likely to cause irreversible serious adverse events. No post-baseline response assessment was available for 24 participants (23.3%) in the control arm and 12 (5.7%) in the combination arm; 17 control participants withdrew consent before treatment. More participants in the combination arm had ECOG performance status 1 (22.9% vs 15.5%) and a largest metastatic lesion of 8.1 cm or more (8.6% vs 4.9%). Subgroups with LDH 2 times the ULN or higher, target lesion 8 cm or larger, or extrahepatic-only metastases had small numbers of participants and 95% confidence intervals that included the null value. Quality of life by the EORTC QLQ-C30 was a stated endpoint, and quality-of-life data were not presented at ASCO 2026. TRAEs led to dose reduction of darovasertib in 23.4% and of crizotinib in 26.4% of participants.
The sources conflict on several figures: the quarterly report for the first quarter of 2026 describes a statistically significant improvement in OS rate, while the presentation and releases describe OS as immature; any-grade TRAEs in the control arm are 89 (89.0%) in the summary table and 88 (88.0%) in the table of common events; treatment-related serious adverse events in the control arm are 25.0% in the presentation and release and 25.3% in the abstract; and one treatment-related fatal adverse event is reported in each arm while the grade 5 hepatic failure in the combination arm is described as considered unrelated by the sponsor.